Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions is pleased to announce its PARTNER study has recruited its first patient. The study, which received formal Health Research Authority (HRA) ethics approval in December 2020 and started recruiting just this month, has been commissioned to gather data for the further development of Physiomics’ personalised oncology dosing tool.
The PARTNER study is an observational clinical trial that will be run by the Portsmouth Technology Trials Unit (PTTU), which is a collaboration between Portsmouth Hospitals University NHS Trust (PHU) and the University of Portsmouth, specialising in clinical trials in new healthcare technologies. First announced in March 2020, the PARTNER study is funded by a ‘Connect’ award from National Institute for Health Research (NIHR) Invention for Innovation programme.
The title of the award project is “Further development of, and evidence generation for a precision tool for optimising chemotherapy dosing in advanced prostate cancer (NIHR201282)”. The award provides 100% reimbursement of project costs of up to £150,000 over the duration of the project which was originally scheduled to end in April 2021 but which has been delayed due to the Covid pandemic (as announced on 10 May 2021). NIHR has now formally agreed that the project will be extended until April 2022, with no change in the total project costs.
In parallel with the UK-based PARTNER study, Physiomics plc is engaged in a collaboration with US company TabulaRasa Healthcare (TRHC), to integrate Physiomics’ personalised dosing software into TRHC’s DoseMeRx® suite of personalised dosing solutions.
Dr Jim Millen, CEO of Physiomics, commented: “We’re very excited that the PARTNER trial is now underway despite all the challenges presented by the current COVID pandemic. I’d like to take the opportunity to thank the doctors, nurses and research team at PHU and University of Portsmouth for their support so far, despite what must have been a really difficult last twelve months. We look forward to monitoring the recruitment going forwards and generating some great data to support the further development of our tool.”
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company’s Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics’ technologies have been confirmed by over 80 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.
About the National Institute for Health Research (NIHR)
The mission of the National Institute for Health Research (NIHR) is to improve the health and wealth of the nation through research. We do this by:
- Funding high quality, timely research that benefits the NHS, public health and social care;
- Investing in world-class expertise, facilities and a skilled delivery workforce to translate discoveries into improved treatments and services;
- Partnering with patients, service users, carers and communities, improving the relevance, quality and impact of our research;
- Attracting, training and supporting the best researchers to tackle complex health and social care challenges;
- Collaborating with other public funders, charities and industry to help shape a cohesive and globally competitive research system;
- Funding applied global health research and training to meet the needs of the poorest people in low and middle income countries.
NIHR is funded by the Department of Health and Social Care. Its work in low and middle income countries is principally funded through UK Aid from the UK government.